Monopar Therapeutics (MNPR) Long-Term Deferred Tax (2020 - 2023)
Monopar Therapeutics (MNPR) posted Long-Term Deferred Tax of $11.1 million for Q4 2022, up 219.77% sequentially from $3.5 million in Q4 2021, and up 219.77% YoY from $3.5 million in Q4 2021.
Monopar Therapeutics (MNPR) Long-Term Deferred Tax (2020 - 2023) Analysis & Trends
Monopar Therapeutics has reported Long-Term Deferred Tax for 3 years, with the latest figure at $11.1 million in Q4 2022.
- Quarterly Long-Term Deferred Tax rose 219.77% year-over-year to $11.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $11.1 million (up 219.77% YoY) and the FY2022 annual result came in at $11.1 million, up 219.77% from the prior year.
- Long-Term Deferred Tax climbed to $11.1 million in Q4 2022 per MNPR's latest filing, from $3.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $11.1 million in Q4 2022 and troughed at $3.5 million in Q4 2021.
- A 3-year average of $6.6 million and a median of $5.2 million in 2020 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax tumbled 33.25% in 2021, then jumped 219.77% in 2022.
- Over 3 years, Long-Term Deferred Tax stood at $5.2 million in 2020, then sank by 33.25% to $3.5 million in 2021, then surged by 219.77% to $11.1 million in 2022.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $11.1 million, $3.5 million, and $5.2 million for Q4 2022, Q4 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13.27 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Dec 31, 2021 | 3.48 Mn |
| Dec 31, 2020 | 5.22 Mn |